condition Inflammatory Bowel Disease

Overview

Inflammatory bowel disease (IBD) is the name for a group of autoimmune diseases characterized by inflammation of the gastrointestinal (GI) tract. The two main types are Crohn’s Disease and ulcerative colitis. Common symptoms include abdominal pain, stomach cramping, diarrhea, and blood in the stool. Many patients also have more bowel movements in a day than usual and a sudden need to immediately have a bowel movement. Procedures like an endoscopy or colonoscopy can diagnose IBD. During these procedures, tissue samples are often taken and sent to a lab to help identify the type of IBD. Without treatment, symptoms often flare up. Severe flares may require hospital care or surgery. No medication can cure IBD, but oral and injectable medications can suppress the symptoms and allow the GI tract to heal.

Drug Therapies

Abrilada (adalimumab-afzb)

Abrilada (adalimumab-afzb) is an FDA-approved, citrate-free, interchangeable biosimilar to Humira. Like Humira, Abrilada is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.

Manufacturer:

Pfizer

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.abrilada.com/

phone:

1-844-722-6672

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older

reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis

reducing signs and symptoms in adult patients with active ankylosing spondylitis

treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older

treatment of moderately to severely active ulcerative colitis in adult patients

treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

treatment of moderate to severe hidradenitis suppurativa in adult patients

treatment of non-infectious intermediate, posterior, and panuveitis in adult patients

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Uveitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Amjevita (adalimumab-atto)

Amjevita (adalimumab-atto) is the first FDA-approved biosimilar to Humira. Like Humira, Amjevita is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Amgen

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.amjevita.com/

phone:

1-888-826-5384

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older

reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis

reducing signs and symptoms in adult patients with active ankylosing spondylitis

reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderate to severely active Crohn’s Disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab

inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine, or 6-mercaptopurine

treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Juvenile Idiopathic Arthritis

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Avsola (infliximab-axxq)

Avsola (infliximab-axxq) is an FDA-approved biosimilar to Remicade. Like Remicade, Avsola is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Amgen

Route of Administration:

Intravenous

Site of Care:

Outpatient

Website:

https://www.avsola.com/

phone:

866-264-2778

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy

reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease

reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy

[in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signa and symptoms in adult patients with active ankylosing spondylitis

reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients

treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Cimzia (certolizumab pegol)

Cimzia (certolizumab pegol) is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthitis, Crohn’s disease, and plaque psoriasis.

Manufacturer:

UCB, Inc.

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.cimzia.com/

phone:

1-866-424-6942

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy

treatment of adults with moderately to severely active rheumatoid arthritis/strong>

treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older

treatment of adult patients with active psoriatic arthritis

treatment of adults with active ankylosing spondylitis

treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation

treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Juvenile Idiopathic Arthritis

Non-Radiographic Axial Spondyloarthritis

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Cyltezo (adalimumab-adbm)

Cyltezo (adalimumab-adbm) is an FDA-approved, citrate-free, interchangeable biosimilar to Humira. Like Humira, Cyltezo is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.

Manufacturer:

Boehringer Ingelheim

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.cyltezo.com/

phone:

1-833-295-8396

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older

reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis

reducing signs and symptoms in adult patients with active ankylosing spondylitis

treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older

treatment of moderately to severely active ulcerative colitis in adult patients

treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

treatment of moderate to severe hidradenitis suppurativa in adult patients

treatment of non-infectious intermediate, posterior, and panuveitis in adult patients

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Uveitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Entocort EC (budesonide)

Entocort EC (budesonide) is a synthetic corticosteroid formulated as a capsule that is used both to treat flares of Crohn’s disease and to maintain remission in certain parts of the gastrointestinal tract.

Manufacturer:

misc.

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon

Conditions:

Crohn’s Disease

Therapeutic Area:

Gastroenterology

less details
Entyvio (vedolizumab)

Entyvio (vedolizumab) is an monoclonal antibody given by either infusion or injection that blocks the integrin receptor to reduce inflammation in inflammatory bowel diseases.

Manufacturer:

Takeda

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

https://www.entyvio.com/

phone:

1-855-ENTYVIO (1-855-368-9846)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of moderately to severely active ulcerative colitis

treatment of moderately to severely active Crohn’s disease

Conditions:

Crohn’s Disease

Ulcerative Colitis

Therapeutic Area:

Gastroenterology

less details
Hadlima (adalimumab-bwwd)

Hadlima (adalimumab-bwwd) is an FDA-approved biosimilar to Humira. Like Humira, Hadlima is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.

Manufacturer:

Organon

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.hadlima.com/

phone:

1-855-460-7928

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older

reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis

reducing signs and symptoms in adult patients with active ankylosing spondylitis

treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older

treatment of moderately to severely active ulcerative colitis in adult patients

treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

treatment of moderate to severe hidradenitis suppurativa in adult patients

treatment of non-infectious intermediate, posterior, and panuveitis in adult patients

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Uveitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Hulio (adalimumab-fkjp)

Hulio (adalimumab-fkjp) is an FDA-approved, citrate-free, interchangeable biosimilar to Humira. Like Humira, Hulio is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.

Manufacturer:

Organon

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.hulio.com/

phone:

1-855-460-7928

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older

reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis

reducing signs and symptoms in adult patients with active ankylosing spondylitis

treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older

treatment of moderately to severely active ulcerative colitis in adult patients

treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

treatment of moderate to severe hidradenitis suppurativa in adult patients

treatment of non-infectious intermediate, posterior, and panuveitis in adult patients

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Uveitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Humira (adalimumab)

Humira (adalimumab) is the original, or “reference,” adalimumab product. Adalimumab is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.

Manufacturer:

AbbVie

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.humira.com/

phone:

1-800-488-6472

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older

reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis

reducing signs and symptoms in adult patients with active ankylosing spondylitis

treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older

treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older

treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older

treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Uveitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Hyrimoz (adalimumab-adaz)

Hyrimoz (adalimumab-adaz) is an FDA-approved biosimilar to Humira. Like Humira, Hyrimoz is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.

Manufacturer:

Sandoz

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.hyrimoz.com/

phone:

1-833-HYRIMOZ (1-833-497-4669)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older

reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis

reducing signs and symptoms in adult patients with active ankylosing spondylitis

treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older

treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older

treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older

treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Uveitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Idacio (adalimumab-aacf)

Idacio (adalimumab-aacf) is an FDA-approved biosimilar to Humira. Like Humira, Idacio is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.

Manufacturer:

Fresenius Kabi

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.kabicare.us/hcp/program/idacio-adalimumab-aacf/

phone:

1-833-KABICARE (1-833-522-4227)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older

reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis

reducing signs and symptoms in adult patients with active ankylosing spondylitis

treatment of moderately to severely active Crohn’s disease in adult patients

treatment of moderately to severely active ulcerative colitis in adult patients

treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

treatment of moderate to severe hidradenitis suppurativa in adult patients

treatment of non-infectious intermediate, posterior, and panuveitis in adult patients

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Uveitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Imuldosa (ustekinumab-srlf)

Imuldosa (ustekinumab-srlf) is an FDA-approved biosimilar to Stelara. Like Stelara, Imuldosa is a monoclonal antibody that blocks the action of interleukins 12 and 23 to reduce inflammation in psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Accord BioPharma

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older

treatment of moderately-to-severely active Crohn’s disease in adults

treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Inflectra (infliximab-dyyb)

Inflectra (infliximab-dyyb) is the first FDA-approved biosimilar to Remicade. Like Remicade, Inflectra is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Pfizer

Route of Administration:

Intravenous

Site of Care:

Outpatient

Website:

https://inflectra.pfizerpro.com/

phone:

1-844-722-6672

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy

reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease

reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy

[in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signa and symptoms in adult patients with active ankylosing spondylitis

reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients

treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Ixifi (infliximab-qbtx)

Ixifi (infliximab-qbtx) is an FDA-approved biosimilar to Remicade. Like Remicade, Ixifi is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Pfizer

Route of Administration:

Intravenous

Site of Care:

Outpatient

Website:

https://www.pfizer.com/products/product-detail/ixifi_for_injection_for_intravenous_use

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy

reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease

reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy

[in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signa and symptoms in adult patients with active ankylosing spondylitis

reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients

treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Omvoh (mirikizumab-mrkz)

Omvoh (mirikizumab-mrkz) is a monoclonal antibody that blocks the action of interleukin 23 to reduce inflammation in Crohn’s disease and ulcerative colitis.

Manufacturer:

Lilly

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

https://omvoh.lilly.com/

phone:

1-800-LillyRx (1-800-545-5979)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of moderately to severely active Crohn’s disease in adults

treatment of moderately to severely active ulcerative colitis in adults

Conditions:

Crohn’s Disease

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Ortikos (budesonide)

Ortikos (budesonide) is a synthetic corticosteroid formulated as an extended-release capsule that is used both to treat flares of Crohn’s disease and to maintain remission in certain parts of the gastrointestinal tract.

Manufacturer:

misc.

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon in patients 8 years and older

Conditions:

Crohn’s Disease

Therapeutic Area:

Gastroenterology

less details
Otulfi (ustekinumab-aauz)

Otulfi (ustekinumab-aauz) is an FDA-approved biosimilar to Stelara. Like Stelara, Otulfi is a monoclonal antibody that blocks the action of interleukins 12 and 23 to reduce inflammation in psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Fresenius Kabi

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

https://biosimilars.fresenius-kabi.com/portfolio/products/otulfi

phone:

1-833-KABICARE (1-833-522-4227)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older

treatment of moderately-to-severely active Crohn’s disease in adults

treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Pyzchiva (ustekinumab-ttwe)

Pyzchiva (ustekinumab-ttwe) is an FDA-approved biosimilar to Stelara. Like Stelara, Pyzchiva is a monoclonal antibody that blocks the action of interleukins 12 and 23 to reduce inflammation in psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Sandoz

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

https://www.pyzchiva.com/pro/

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older

treatment of moderately-to-severely active Crohn’s disease in adults

treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Remicade (infliximab)

Remicade (infliximab) is the original, or “reference,” infliximab product. Infliximab is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Johnson & Johnson

Route of Administration:

Intravenous

Site of Care:

Outpatient

Website:

https://www.remicade.com/

phone:

877-CarePath (877-227-3728)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy

reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease

reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy

[in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease

reducing signa and symptoms in adult patients with active ankylosing spondylitis

reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients

treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Renflexis (infliximab-abda)

Renflexis (infliximab-abda) is an FDA-approved biosimilar to Remicade. Like Remicade, Renflexis is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Organon

Route of Administration:

Intravenous

Site of Care:

Outpatient

Website:

https://www.renflexis.com/

phone:

866-847-3539

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy

reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease

reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy

[in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signa and symptoms in adult patients with active ankylosing spondylitis

reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients

treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Rinvoq (upadacitinib)

Rinvoq (upadacitinib) is a Janus kinase inhibitor approved to reduce the inflammation in rheumatoid arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, polyarticular juvenile idiopathic arthritis, and giant cell arteritis.

Manufacturer:

AbbVie

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

https://www.rinvoq.com/

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers

treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers

treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable

treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers

treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers

treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers

treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy

treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers

Conditions:

Atopic Dermatitis

Ankylosing Spondylitis

Crohn’s Disease

Juvenile Idiopathic Arthritis

Non-Radiographic Axial Spondyloarthritis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Selarsdi (ustekinumab-aekn)

Selarsdi (ustekinumab-aekn) is an FDA-approved biosimilar to Stelara. Like Stelara, Selarsdi is a monoclonal antibody that blocks the action of interleukins 12 and 23 to reduce inflammation in psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Alvotech USA | Teva

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older

treatment of moderately-to-severely active Crohn’s disease in adults

treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Simlandi (adalimumab-ryvk)

Simlandi (adalimumab-ryvk) is an FDA-approved, interchangeable biosimilar to Humira. Like Humira, Simlandi is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.

Manufacturer:

Teva Pharmaceuticals

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.simlandi.com/

phone:

1-888-587-3263

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older

reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis

reducing signs and symptoms in adult patients with active ankylosing spondylitis

treatment of moderately to severely active Crohn’s disease in adult patients

treatment of moderately to severely active ulcerative colitis in adult patients

treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

treatment of moderate to severe hidradenitis suppurativa in adult patients

treatment of non-infectious intermediate, posterior, and panuveitis in adult patients

Conditions:

Nkylosing Spondylitis

Crohn’s Disease

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Uveitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Simponi (golimumab)

Simponi (golimumab) is a monoclonal antibody given by self-injection that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

Manufacturer:

Johnson & Johnson

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.simponi.com/

phone:

1-877-CarePath (1-877-227-3728)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of adult patients with moderately to severely active rheumatoid arthritis in combination with methotrexate

treatment of adult patients with active psoriatic arthritis alone, or in combination with methotrexate

treatment of adult patients with active ankylosing spondylitis

inducing and maintaining clinical response, improving endoscopic appearance of the mucosa during induction, achieving clinical remission, and achieving and sustaining clinical remission in induction responders in adult patients with moderately to severely active ulcerative colitis with an inadequate response or intolerance to prior treatment or requiring continuous steroid therapy

Conditions:

Ankylosing Spondylitis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Skyrizi (risankizumab-rzaa)

Skyrizi (risankizumab-rzaa) is a monoclonal antibody that blocks the action of interleukin 23 to reduce inflammation in plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Manufacturer:

AbbVie

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

https://www.skyrizi.com/

phone:

1-866-759-7494

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

treatment of active psoriatic arthritis in adults

treatment of moderately-to-severely active Crohn’s disease in adults

treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Starjemza (ustekinumab-hmny)

Starjemza (ustekinumab-hmny) is an FDA-approved biosimilar to Stelara. Like Stelara, Starjemza is a monoclonal antibody that blocks the action of interleukins 12 and 23 to reduce inflammation in psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Hikma

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

https://starjemza.com/taking-starjemza

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older

treatment of moderately-to-severely active Crohn’s disease in adults

treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Stelara (ustekinumab)

Stelara (ustekinumab) is the original, or “reference,” ustekinumab product. Ustekinumab is a monoclonal antibody that blocks the action of interleukins 12 and 23 to reduce inflammation in psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Johnson & Johnson

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

https://www.stelarainfo.com

phone:

877-CarePath (877-227-3728)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older

treatment of moderately-to-severely active Crohn’s disease in adults

treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
SteQeyma (ustekinumab-stba)

SteqQeyma (ustekinumab-stba) is an FDA-approved biosimilar to Stelara. Like Stelara, SteQeyma is a monoclonal antibody that blocks the action of interleukins 12 and 23 to reduce inflammation in psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Celltrion

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

https://www.steqeyma.com

phone:

1-877-81CONNECT (1-877-812-6662)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older

treatment of moderately-to-severely active Crohn’s disease in adults

treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Tremfya (guselkumab)

Tremfya (guselkumab) is a monoclonal antibody that blocks the action of interleukin 23 to reduce inflammation in plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Manufacturer:

Johnson & Johnson

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

https://www.tremfyahcp.com/

phone:

844-4withMe (844-494-8463)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy

treatment of active psoriatic arthritis in adults

treatment of moderately-to-severely active Crohn’s disease in adults

treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Uceris (budesonide)

Uceris (budesonide) is a synthetic corticosteroid formulated as an extended-release tablet and used to treat flares of ulcerative colitis.

Manufacturer:

misc

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

induction of remission in patients with active, mild to moderate ulcerative colitis

Conditions:

Ulcerative Colitis

Therapeutic Area:

Gastroenterology

less details
Velsipity (etrasimod)

Velsipity (etrasimod) targets the sphingosine 1-phosphate receptor and reduces symptoms in ulcerative colitis. Unlike Zeposia, Velsipity is not approved for use in multiple sclerosis.

Manufacturer:

Pfizer

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

https://velsipity.com

phone:

1-800-350-3080

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Ulcerative Colitis

Therapeutic Area:

Gastroenterology

less details
Wezlana (ustekinumab-auub)

Wezlana (ustekinumab-auub) is an FDA-approved biosimilar to Stelara. Like Stelara, Wezlana is a monoclonal antibody that blocks the action of interleukins 12 and 23 to reduce inflammation in psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Amgen

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older

treatment of moderately-to-severely active Crohn’s disease in adults

treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Xeljanz (tofacitinib)

Xeljanz (tofacitinib) is a Janus kinase inhibitor approved to reduce the inflammation in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and polyarticular juvenile idiopathic arthritis.

Manufacturer:

Pfizer

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

https://xeljanz.pfizerpro.com/

phone:

1-844-935-5269

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers

treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers

treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers

treatment of adult patients with moderately-to-severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers

treatment of active polyarticular course juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers

Conditions:

Atopic Dermatitis

Ankylosing Spondylitis

Crohn’s Disease

Juvenile Idiopathic Arthritis

Non-Radiographic Axial Spondyloarthritis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Yesintek (ustekinumab-kfce)

Yesintek (ustekinumab-kfce) is an FDA-approved biosimilar to Stelara. Like Stelara, Yesintek is a monoclonal antibody that blocks the action of interleukins 12 and 23 to reduce inflammation in psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Manufacturer:

Biocon Biologics

Route of Administration:

Intravenous, Subcutaneous

Site of Care:

Outpatient

Website:

phone:

1-844-348-3404

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older

treatment of moderately-to-severely active Crohn’s disease in adults

treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Crohn’s Disease

Plaque Psoriasis

Psoriatic Arthritis

Ulcerative Colitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Yuflyma (adalimumab-aaty)

Yuflyma (adalimumab-aaty) is an FDA-approved, citrate-free biosimilar to Humira. Like Humira, Yuflyma is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.

Manufacturer:

Celltrion

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.yuflyma.com/

phone:

1-877-81CONNC (1-877-812-6662)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older

reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis

reducing signs and symptoms in adult patients with active ankylosing spondylitis

treatment of moderately to severely active Crohn’s disease in adult patients

treatment of moderately to severely active ulcerative colitis in adult patients

treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

treatment of moderate to severe hidradenitis suppurativa in adult patients

treatment of non-infectious intermediate, posterior, and panuveitis in adult patients

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Uveitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Yusimry (adalimumab-aqvh)

Yusimry (adalimumab-aqvh) is an FDA-approved biosimilar to Humira. Like Humira, Yusimry is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.

Manufacturer:

Coherus

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.yusimry.com/

phone:

1-800-YUSIMRY (1-800-987-4679)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis

reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older

reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis

reducing signs and symptoms in adult patients with active ankylosing spondylitis

treatment of moderately to severely active Crohn’s disease in adult patients

treatment of moderately to severely active ulcerative colitis in adult patients

treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

treatment of moderate to severe hidradenitis suppurativa in adult patients

treatment of non-infectious intermediate, posterior, and panuveitis in adult patients

Conditions:

Ankylosing Spondylitis

Crohn’s Disease

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis

Plaque Psoriasis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Uveitis

Therapeutic Area:

Dermatology
Gastroenterology
Rheumatology

less details
Zeposia (ozanimod)

Zeposia (ozanimod) targets the sphingosine 1-phosphate receptor and reduces symptoms in multiple sclerosis and ulcerative colitis.

Manufacturer:

Bristol Myers Squibb

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

https://www.zeposia.com/

phone:

1-833-ZEPOSIA (1-833-937-6742)

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

Multiple Sclerosis

Ulcerative Colitis

Therapeutic Area:

Gastroenterology
Neurology

less details
Zymfentra (infliximab-dyyb)

Zymfentra (infliximab-dyyb) is an FDA-approved biosimilar to Remicade and the only self-administered infliximab product currently approved. Like Remicade, Zymfentra is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in Crohn’s disease and ulcerative colitis.

Manufacturer:

Celltrion

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.zymfentra.com

phone:

1-877-81CONNC (1-877-812-6662)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

maintenance treatment of moderaly to severely active ulcerative colitis in adults following treatment with an infliximab product administered intravenously

maintenance treatment of moderately-to-severely active Crohn’s disease in adults following treatment with an infliximab product administered intravenously>

Conditions:

Crohn’s Disease

Ulcerative Colitis

Therapeutic Area:

Gastroenterology

less details

Resources

Understanding a diagnosis can feel overwhelming. These resources link to well-established organizations, for in-depth education, research, and support.

CDC – IBD

Crohn’s & Colitis Foundation of America (CCFA)

IBD vs. IBS – CCFA

Stay Connected

Get the latest news and updates

Contact Us Now

condition Inflammatory Bowel Disease

Overview

Drug Therapies

Abrilada (adalimumab-afzb)

Approved Indication:

Conditions:

Therapeutic Area:

Amjevita (adalimumab-atto)

Approved Indication:

Conditions:

Therapeutic Area:

Avsola (infliximab-axxq)

Approved Indication:

Conditions:

Therapeutic Area:

Cimzia (certolizumab pegol)

Approved Indication:

Conditions:

Therapeutic Area:

Cyltezo (adalimumab-adbm)

Approved Indication:

Conditions:

Therapeutic Area:

Entocort EC (budesonide)

Approved Indication:

Conditions:

Therapeutic Area:

Entyvio (vedolizumab)

Approved Indication:

Conditions:

Therapeutic Area:

Hadlima (adalimumab-bwwd)

Approved Indication:

Conditions:

Therapeutic Area:

Hulio (adalimumab-fkjp)

Approved Indication:

Conditions:

Therapeutic Area:

Humira (adalimumab)

Approved Indication:

Conditions:

Therapeutic Area:

Hyrimoz (adalimumab-adaz)

Approved Indication:

Conditions:

Therapeutic Area:

Idacio (adalimumab-aacf)

Approved Indication:

Conditions:

Therapeutic Area:

Imuldosa (ustekinumab-srlf)

Approved Indication:

Conditions:

Therapeutic Area:

Inflectra (infliximab-dyyb)

Approved Indication:

Conditions:

Therapeutic Area:

Ixifi (infliximab-qbtx)

Approved Indication:

Conditions:

Therapeutic Area:

Omvoh (mirikizumab-mrkz)

Approved Indication:

Conditions:

Therapeutic Area:

Ortikos (budesonide)

Approved Indication:

Conditions:

Therapeutic Area:

Otulfi (ustekinumab-aauz)

Approved Indication:

Conditions:

Therapeutic Area:

Pyzchiva (ustekinumab-ttwe)

Approved Indication:

Conditions:

Therapeutic Area:

Remicade (infliximab)